INTS vs MRNA · $7.7M cap vs rev $1.94B
Intensity Therapeutics, Inc. Common stock (INTS) versus Moderna Inc (MRNA) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stephane Bancel.
INTS does not have a complete income-statement cache yet.
Latest reported MRNA revenue for 2025-12-31 was $1.94B. Net income was -$2.82B. Revenue was down 39.9% from 2024-12-31 to 2025-12-31. MRNA currently screens at market cap $24.52B.
INTS currently screens at market cap $7.7M. MRNA currently screens at market cap $24.52B.
Not investment advice. Open the INTS and MRNA stock pages for the full models.
Not investment advice.